A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

NCT03602859 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1400

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

Interventions

DRUG: Niraparib
DRUG: Dostarlimab (TSR-042)
DRUG: Standard of care
DRUG: Dostarlimab-Placebo
DRUG: Niraparib-Placebo

Sponsor

Tesaro, Inc.

Collaborators

[object Object]